Medicure Inc. (MPH.V)

Website
Yahoo Finance
Filing

Dec. 03, 2018
Q3 2018 Data
Price: $6.25, Shares:15.7m, Cap: $98m
1.Business Information
(1) History 
The company was found by Dr. Albert Friesen at around 1997. It was created to develop a medicine called MC-1 for Cardiovascular disease. The company IPOed at 1999 to raise more fund for the research. The clinical trial was going well until it failed to pass phase III at 2007 after spending like over $130m on the research and it incurred $30m in debt as well.

The company almost bankrupted at that time but luckily in 2006, it acquired the US right to another  Cardiovascular medicine called Cardiovascular AGGRASTAT. Since 2007, revenue related to AGGRASTAT started to pick up but was very low. At 2011 it restructured its debt by issuing shares.  By 2014 AGGRASTAT's revenue raised to over $8m and became profitable since then. AGGRASTAT continue to doing very well and achieved over $30m in revenue and $9m in EBITDA at 2016. At 2007, competition kicked in. The company lowered AGGRASTAT's price. Although the volume of AGGRASTAT still increases but revenue dropped to $27m and EBITDA dropped to $4.5m. For the first 3Q 2018, volume still increased, but revenue is flat and EBITDA is lower than $2m.

Since 2014, the company started to invest in a generic medicine factory in the US called Apicore. Gradually the company increased its stake in the company and later at 2017 it sold Apicore and made around $70m in profit.

(2) Major business.
AGGRASTAT: Currently quarterly revenue is around $7m and EBITDA is $0.5m. Also, the product's patent will expire at 2023.

Zypitamag: Started sale at Q2 2018, generated $600k and $300k revenue in Q2 and Q3.

Sodium Nitroprusside: Generic for Nitropress. Will start to sale at Q1 2019.


(3) Debt and Credit Facility.
$72m in cash and no debt.

(4) Employee numbers


(5) Industry comparison.


(6) Major events

2. Management
(1) Key person
Albert Friesen: Ph.D. in protein chemistry from the University of Manitoba, the major creator of WinRho SDF which seems to be Canada's first successful bioproduct. He was also involved in many products after that. 


(2) Insider ownership
Albert Friesen:  15%.


3. Financial data.


4. Valuation
(1)Currently, the company has $72m in cash and it is likely to get another $13m by 2019. Although AGGRASTAT's profit is trending down, the company is still profitable. Remove the cash, the company is just traded at around $10-$20m.

(2) It has one profitable product(AGGRASTAT), one just-launched product (Zypitamag), one approved product (Generic Nitropress), 2 products waiting for approval.

5. Risk
(1) AGGRASTAT's revenue and profit are trending down. It might become unprofitable.

(2) The company might not use the cash wisely.

6. Conclusion
Overall the company is in a good condition and there are pretty good potentials to do well in the future. Current price is quite cheap.

7.Links


BioSyent Inc. (RX.V)

Website
Yahoo Finance
Filing

Nov. 25, 2018
Q3 2018 Data
Price: $7.45, Shares: 14.5m, Cap: $108m
1.Business Information
(1) History 
The company was called Hedley Technologies before 2006. It was founded at the early 1990s and IPOed at around 1997. Its major product is called Protect-It which is an insecticide product. Revenue is very low at around 700k for many years until 2006 which generates $1.5m sales but soon fell back to $1m level in 2007. After that, the revenue from it just stays below $1m. In 2017, revenue increased to $1.4m and then at first 3Q 2018, it fell back to $1m level again.

In 2006 the company created a new subsidiary called BioSyent Pharma Inc. Also, it changed its name to BioSyent which aimed to launch new pharmaceutical products.  In 2007, the company launched a new iron supplements product FeraMax. It turns out to be a very successful product. Revenue from it reaches $2m in 2011 and the company turns into profitable since then. By estimate, revenue for FeraMax might reach $11m-$13m. Very impressive, however, it seems FeraMax revenue had stopped growing at 2018.

(2) Major business.
Protect-it: A pest control product which is its original business. Currently, it still generates around $1m/year sales.

FeraMax 150 & Powder: OTC Iron supplements mainly for female. This is its major product, might count 60%-70% of its total revenue right now.

Cathejell: a surface anesthesia product. Might count around 10% to 20% of revenue.

CYSVIEW® Blue-Light Cystoscopy: A product used in bladder tumor remove procedure. Current revenue from this is still pretty low but grows very well.

(3) Debt and Credit Facility.
Currently, there is $22m in cash and no debt.

(4) Employee numbers


(5) Industry comparison.


(6) Major events

2. Management
(1) Key person
Rene Goehrum is the current CEO. He joined the company in 1996 and became CEO at 1999. Previously he was doing marketing for Procter & Gamble. He seems to be more a business person.


(2) Insider ownership
Rene Goehrum holds 2.3m share around 16% of total 14.5m shares.  At 2001, he owns 700k shares of total 9m shares.


3. Financial data.


4. Valuation
(1) Currently, it is trading around 11 EV/EBITDA which is not very expensive compared to the same industry. However, if the company can't grow its revenue further, the price is actually not cheap.

(2) It has $22m in the balance sheet which can be put into new acquisitions. Also, several products other than FeraMax does have some growth potential.


5. Risk
(1) The company's growth for the past several years is mainly driven by FeraMax sales. It seems it had reached the mature state. Also, since FeraMax is not patented, the competition might even decrease the sales of FeraMax.

(2) It is hard to tell whether those other products can keep the company growing.



6. Conclusion
Overall the company was well managed with some growth potential. Current price is not very cheap if the company stop growing its revenue. However, it does have some potential to do well in the future.

7.Links


Imaflex Inc. (IFX.V)

Website
Yahoo Finance
Filing

Nov. 08, 2018
Q3 2018 Data
Price: $0.80, Shares: 50m, Cap: $40m
1.Basic Information
(1) History 
The company was found by Joseph Abbandonato, Tony Abbandonato, and Gerald R. Phelps at 1993. It produces plastic films for the food industry. Previously, Joseph found another company in the same industry and sold it. The company went IPO at 1999 through a reverse merger. Both 3 of them are still in the company and Joseph is still the current CEO.
Since the beginning, its main product is its plastic film used in packaging and bags. Later it produces metalized films for agriculture usage. It has been doing very well for the first 10 years with revenue growing from almost none to $50m in 2005. EBITDA also reached over $7m. However, from 2006 to 2012, it suffered major industry overcapacity and other issues. Revenue stays below $50m and just stay profitable. From 2013 to 2017, revenue grew close to $90m. However, profit stays low until 2017 which generates $7.8m EBITDA again.
Since 2014, the company started to develop two new films which are still not generating big revenue yet. But both seem to have some potential.

(2) Business-related.
(1) Regular film and bags: this is its core business. Garbage bags, films for others etc.

(2) Metalized film for plant protection:

(3) Shine N’ Ripe: A special film to fight citrus greening. It has generated $6.4m revenue in 2017.

(4) ADVASEAL: A special slow release film to protect plants. Still under development.


(3) Management.
Joseph is the CEO from the beginning. Before his first company, he worked for 10 years at 2 different plastic company. After selling his first company, he lost some money in another new startup. Later he still started the current company. The company was managed fairly well and been profitable for many years. Also, he had led the company through some difficult years from 2007 to 2012. The company has been profitable since IPO. Also, management compensation is very low in my opinion. Also, although the company's share base has been grown from 19m to 50m, he has maintained his 30% share.

(4) Debt and Credit Facility.
Around $10m in debt and around 5% to 6% interest rate.

(5) Insider holding, options, Insider trading info, share buyback.
Joseph holds 14.5m shares. around 30%. Similar percentage as of 2001.

(6) Employee numbers
241 employees which 160 in Canada and rest are in the U.S.



(7) Industry comparison.


(8) Major events


2. Financial data.


3. Valuation
(1) Currently, the company is making close to $4m profit out of $80m in sales. It is traded around just 10 P/E. However, the company only generated minimal profit for 10 years before 2017.

(2) The two new agriculture films do have some potential if turns out good.

4. Risk
(1) Before 2017, its profitability was lower for several years. It might not be able to sustain its current sales and profit level.

(2) Generally, the plastic film industry is very competitive with low margin. It is not a very attractive industry to invest in.

5. Conclusion
Overall the company was well managed with some growth potential. If the company can maintain the current revenue and profit level, the price is cheap.


6.Links
https://www.youtube.com/watch?v=JyTWIkfUHWI

Questor Technology Inc. (QST.V)

Website
Yahoo Finance
Filing

Sept. 20, 2018
Q2 2018 Data
Price: $2.45, Shares: 26.5m, Cap: $65m
1.Basic Information
(1) History 
The company was founded in 1994. Daniel Motyka joined the company in 1995 and led the IPO in 1997. It developed waste gas combustion equipment that can be used in the gas and oil industry to control methane flaring and emission.

In 1999, Audrey Mascarenhas joined the company to help improve the product. She was an engineer for 17 years and retired at that time. Later in 2005, Audrey replaced Daniel as CEO of the company and led the company up to now. She has an incredible story as a female working in the oil and gas industry.

The company's revenue was quite low at the beginning and reached $2m in 2005, then over $3m in 2006. In 2007, it had a one-time revenue boost of $6m from a China sale. Revenue continue to grow to over 12m in 2014. In 2015 and 2016, revenue dropped to $7-8m level but recovered to over $19m in 2017.

(2) Business-related.
Methane Incinerator: This is its main product. The incinerator has an efficiency of 99.9% compared to just a 60% level if just flaring methane. It has no visible flare as well. Also significantly improves air quality and smells.  Previously it sells its incinerator to its customer.  Now it relies more on rental revenue which provides more flexibility for its customers.

Currently, rental revenue counts for over 60% of its revenue. Rental seems to have a higher gross margin.

The company was actually very profitable. Its gross margin has improved to over 50% which is very impressive. Also, its SG&A ratio is getting down to just 15% right now.

The company's business is heavily concentrated in Colorado. Mainly because the state has a strict methane emission regulation. In Sept. 2018, the US government signed a rollback on federal methane regulation signed at Obama time. Thus causing the stock to fall from over $4 to the $2 level.


(3) Management.
Audrey Mascarenhas: She is a very talented engineer and seems to manage the company very conservatively. The company's shares since 2002 were 23.4m and now are 26.4m. It was profitable since then.

(4) Debt and Credit Facility.
$5m cash and no debt.

(5) Insider holding, options, Insider trading info, share buyback.
Audrey Mascarenhas: 4.3m, 16%.

(6) Employee numbers


(7) Industry comparison.


(8) Major events


2. Financial data.


3. Valuation
(1) Currently, the company generates over $2m/quarter in income. It is traded at just around 8 P/E which is very cheap. Obviously, people are expecting the company's revenue will shrink significantly because of the regulation change. If the revenue shrinks by half, it still could get around $4m/year of income, the current price is still acceptable.

4. Risk
(1) The regulation change is obviously the biggest risk the company is facing right now. However, Colorado has indicated that it will not changes its regulation. Also, just from a cultural point of view, I don't think its customers will suddenly end those rentals and start burning methane. But for new projects, the oil and gas company may choose not to use the company's product. It is possible that its revenue will shrink for quite a while. But I believe it will be a slow process.

(2) Its revenue is concentrated in Colorado which is quite a risk.

5. Conclusion
Overall the company was very well managed and has good growth potential. Although there are some risks, I think the current price is very attractive.


6.Links
http://www.investorfile.com/blog/blogcat.asp?catid=341

https://www.youtube.com/watch?v=DGOLcI6ga0k


Update: July 31, 2022
Price: 0.98. Shares: 27.8m. Cap: $27m.
1. It has been quite a hard time for the company during the last two years as its major rental customer filed for bankruptcy in early 2020. Now its rental revenue is around $0.5/quarter vs $4m/quarter at the highest point. Equipment sale was also down a lot with only $4.1m in 2020 and $2.6 in 2021 vs $12m in 2019.  The company's 2020 cash flow is positive while in 2021 it burned around $2.5m. 

2. So far in Q1 2022, its equipment sale is $1.6m. In Q2 2022. It is expected to have similar equipment sales as in Q1.  It also has $4.9m committed equipment sales in total. 

3. In late 2021, Sustainable Development Technology Canada (“SDTC”) signed a Waste Heat to Power generation product development project with the company with $4.5m funding. The first $0.75m was received in Q1 2022. 

4. Currently, it has around $15.8m in cash which is actually $2m higher than at the end of 2019. The main reason for this is a $1m interest-free loan from the government and the $0.75m received recently, plus some working capital changes.

5. With higher equipment sales and the $4.5m funding from SDTC, it is more than likely that the company will achieve a cash flow positive in the near future. 

6. Generally speaking, the outlook of the company is going up. Although it is hard to tell when it will really turn around. It would be very positive if we can see its rental revenue going up as well.  

7. Removing the cash, the company is trading around just $12m. It is much less than its hard asset. The price is very acceptable as long as it can maintain cash positive. 

8. On the negative side, the company seems not doing so great in marketing and capital allocation. It might not need to be so conservative. 








Centric Health Corporation (CHH.TO)

Website
Yahoo Finance
Filing

Sept. 04, 2018
Q2 2018 Data
Price: $0.25, Shares: 208m, Cap: $52m
1.Basic Information
(1) History 
The company was found by Brenda Rasmussen at around 2001 and originally was called Alegro Health Corp. It acquires private clinics in 2003. In 2007, it started to partner with Global Healthcare Investments Solutions (GHIS), a company found by South African entrepreneur Jack Shevel. Previously Jack Shevel created a healthcare company in South Africa called Net Care and grew it into a billion-dollar business. With the fund injected by GHIS, Alegro acquires more clinics and pharmacies. In 2009, after GHIS gain controlling stack of Alegro, it changed its name to Centric Health and Jack Shevel replaced Brenda Rasmussen as CEO. Brenda later left the company and created a new healthcare venture called Premier Health. Jack Shevel managed the company briefly and hired several new CEOs from outside. Mainly David Cutler from 2012 to 2017, then David Murphy starting in 2018.

At the time of IPO around 2003, the company had a revenue of around just $6m. Since 2009, its revenue starts to shoot up mainly by acquisition. By 2013, it reached the highest annual revenue of $456m. Since 2014, the company started to divest its business segments. Mainly the Physiotherapy, Rehabilitation and Assessments segment at 2015 for over $200m to pay down its debt. Its revenue rolls back to $160m level since 2015.

(2) Business-related.
Specialty Pharmacy: Fulfillment center for nursery home etc. Serving around 28,700 patients. Accounts around 3/4 of revenue and 3/4 of adjusted EBITDA. However, since 2018, there is a significant reduction in EBITDA for this segment because of government policy changes. At Q2 2018, EBITDA form this segment is only $2.7m compared to $2.2m in the other segment.

Surgical and Medical Centres: Currently it operates 5 surgery centers across Canada for some specialty surgeries. It counts for 1/4 of revenue but EBITDA has been growing pretty well. Utility ratio currently is around 41%.

The company also has a small equity interest in a device called Karie which dispense medical for older people automatically at home. It could generate around $50 monthly revenue. Currently the device still in the marketing stage.

(3) Management.
Jack Shevel: He was very successful in his previous Netcare business. However, as for Centric Health, it hard to tell how he did it. The company obviously was too aggressive from 2010 to 2013.  It was a right decision to deleverage the business. Overall he seems to care about the business.

(4) Debt and Credit Facility.
Currently, it has around $81m in debt.

(5) Insider holding, options, Insider trading info, share buyback.
Jack Shevel and two others from GHIS own around 85m shares. around 40%.

(6) Employee numbers


(7) Industry comparison.


(8) Major events



2. Financial data.


3. Valuation
(1) Currently, the company has around $16m in annual EBITDA, EV around $130m. Seems not very expensive. However, in cash bases, it operates just even which means no profit left for pay down debt.

(2) The company indicates that it will divest more business to pay down debt to around 3.5 times of the EBITDA. Currently, it is around 5 times.

(3) Today as Sept. 5, 2018, the company released a news of having a supply agreement with Spectrum Cannabis for supply Medical Cannabis to seniors. As a result, the share price jumped to $0.34 now. I view it as unreasonable but it had made the company no more attractive.

(4) As stated in the Q2 2018 conference, Q3 2018 financial might be even worse than Q2.

4. Risk
(1) The governments in Canada tend to be unfriendly towards private healthcare provider. Recent changes in pharmacy pricing hit the company pretty hard. The surgical center business might also be affected by government policies.

(2) Its debt is still too high and should go down to $50m level at least.

5. Conclusion
Overall I think the company has a large chance to turn around. However, the current price is no more attractive. Wait to see what will happen after Q3.

6.Links


iFabric Corp. (IFA.TO)

Website
https://www.coconutgroveintimates.com/
Yahoo Finance
Filing

Sept. 02, 2018
Year end: Sept. 30th
Q3 2018 Data
Price: $1.85, Shares: 26.2m, Cap: $48m
1.Basic Information
(1) History 
The company was founded by Hylton Karon in 1985. Originally it was called Coconut Grove Textiles. Its main business was women's intimate apparel likes bra and underwear etc. In 2008, it also formed an Intelligent Fabrics Division("IFTNA") which aimed to create the fabric with a special characteristic that could be used in medical or sports etc.

It was IPOed at 2012 through a reverse merger and Coconut Grove became a subsidiary of iFrabric Corp. In 2012, it has revenue of around 6m and a just break-even profit. The revenue is mainly from intimate apparel division.  In 2013, its revenue increased to $8.2m. In 2014 revenue grew to $13m mainly because it signed new sleepwear license with the existing customer. The company was uplisted to TSE in 2015.  In the next 3 years, the intimate apparel slows down but the IFTNA division has picked up revenue to over $6m in 2017. The share price was up to over $5 in early 2014 and stay over $3 for a long time.

Since Q2 2018, especially in Q3 2018, both divisions were down. First, the company decided to phase out the sleepwear line which caused the intimate apparel division revenue down by 25%. Also, its IFTNA division was down by 50% because of one customer changed factory from China to another country. As a result, shares price droped to below $2 lately.

(2) Business-related.
Intimate apparel division: Bra, underwear, sleepwear etc. The company signed a contract with Maidenform at 2012. Later renewed for 4 years at 2014. Then in 2018, renewed for another 2 years. Recent revenue from this division was around $12m/year.  The company discontinued the sleepwear business lately. The reason for this is that the sleepwear carries lower margin and facing tough competition lately. Without the sleepwear business, it might be down to less than $10m/year.

IFTNA division: It carries several branded fabric techniques and was doing very well during the past several years. It seems to carry better margin than the intimate apparel division. Overall this has very more growth potential than the intimate apparel business.

(3) Management.
Hylton Karon: He is the original founder and has a textile background. Overall the business was staying profitable and rarely issued any new shares.

(4) Debt and Credit Facility.
$4.7m in cash and $1.4m in the bank loan.

(5) Insider holding, options, Insider trading info, share buyback.
Hylton Karon and his wife each own around 9.5m shares which counts over 73% of total shares.
Hilton Price: CFO, 400k shares, 1.5%.

(6) Employee numbers
It has 29 employees in 2014, reduced to 28 in 2015,  further reduced to 24 in 2016 and 2017.

(7) Industry comparison.


(8) Major events



2. Financial data.


3. Valuation
(1) The company generated around 1.6m income in 2017. $1.4m for the first 2 quarters of 2018. Besides those, it never made any serious money. However, it should mention that all the R&D in the IFTNA division are buried in the expense of those years. Still, it is very likely that the company won't be very profitable in the new future. So based on profit, it is not a cheap stock.

(2) Generally, I believe the company will be profitable and may make $1m to $2m income again. If the IFTNA division is growing again, then it might be able to achieve a higher profit in the future.

(3) I did view the decision to discontinue the sleepwear business is a right decision. Although it created temporary revenue down pressure.

(4) The company outsource its product in Asia and only has 24 employees. The SG&A was actually down in 2017 while the revenue was up. With the elimination of the sleepwear business, it might reduce the number even further.

4. Risk
(1) It is business is contract based. Lose of its major customer will affect the business significantly.

(2) It revenue might shrink even further in the near future. Even make it unprofitable although not very likely.

(3) The CEO family owns way too many shares which make the shares unattractive to the institutional investors.

5. Conclusion
The company seems very managed and does has some potential do very well. It is likely to remain profitable. However, the current price is not very cheap and there is some risk that the business might go bad.

6.Links
http://www.cbc.ca/player/play/2500386027

Opsens Inc. (OPS.TO)

Website
Yahoo Finance
Filing

Aug. 16, 2018
Q3 2018 Data, Year end: Aug. 31th
Price: $0.90, Shares: 90m, Cap: $81m
1.Basic Information
(1) History 
At 1994  Claude Belleville, GaĆ©tan Duplain, both are optical specialists,  co-founded FISO Technologies Inc. at Quebec city. The company is specialized in fiber optical sensors. It was acquired by Roctest in the same year. Later in 2003, they left the company and joined by Pierre Carrier who was CEO of Roctest at that time, a geologist, founded Opsens Inc.  The new company was trying to apply the optical sensors in the oil and gas sector. Carrier took the CEO role and the company IPOed in 2006 and gradually grew its revenue. By 2012, it hit revenue of $6.3m in the oil and gas sector. However, since then the oil and gas revenue started to drop and only generated $1.5m in revenue in 2017.  At Jan. 2013, following by $5m distribution rights contract for the medical sector, Carrier stepped down from CEO role and the CFO Louis Laflamme replaced him as new CEO. Since then, the medical sector has been picked up and reached $12m in 2017.  For the first 3Q of 2018, its medical sector generated around $15m in revenue.

(2) Business-related.
Opto-wire: This is its main product. It is a guidewire with an optical sensor. Compare to the traditional electric based sensor, it seems more reliable and accurate. The major problem with the electric sensor is drifting which creates unreliable data. The optic sensor has much less drifting.


(3) Management.
Pierre Carrier: The original CEO until Jan 2013. At 2014 he resigned from director position as well.
Louis Laflamme: He is the original CFO and replaced Carrier as CEO since 2013. He has been with the company since IPO.

(4) Debt and Credit Facility.
$12m in cash and around $1m in debt.

(5) Insider holding, options, Insider trading info, share buyback.
Claude Belleville: 4.1m shares, 4.6%.
GaƩtan Duplain: 3.7m share. around 4.2%.
Pierre Carrier:  by 2013, he is still holding 3.1m shares. Not mentioned since 2014.
Louis Laflamme: 440k shares. 

(6) Employee numbers


(7) Industry comparison.
St. Jude Medical, Inc. and Volcano Corporation: Electric sensor guidewire. They are the major market shareholders.

ACIST: fiber optic sensors combined with a microcatheter used over a standard guidewire. ACIST sue the company in 2011 for patent issues and later at 2012 both company withdraw the lawsuit.

Boston Scientific: Guidewire with Optic Sensor. Its main product called COMET optic guidewire.

I think both ACIST and Boston Scientific are the direct competitor of the company. Boston Scientific's product seems very close to Opsens's. However, since the traditional electric sensor takes over 80% of the market share, there is plenty of room for them to grow.

(8) Major events
In 2010, it signed a co-development agreement with NASDAQ company Abiomed to using its optical sensor in Abiomed's product. Later in 2014, they changed it to a USD$6m licensing agreement which Abiomed had paid OPS USD$1.5m in 2014, USD$0.75m in 2017, USD$1.25m in 2018, USD$1.75m in Q1 2019. There is still USD$0.75m left to pay within this agreement.


2. Financial data.


3. Valuation
(1) Currently, the company lost around 0.8m per quarter. It has never made any money but losses have been reduced quite a bit recently.

(2) If just based on revenue, it generates around 20m revenue currently. The current market cap is close to 4 times its annual revenue. Not really cheap.

4. Risk
(1) it still loses money and might need to raise money again.

(2) Its revenue growth might slow down or even drop in the medical sector. Don't really know what its advantage over its competitors.

(3) The sales and marketing expense counts almost 40% of total revenue. If it can't get it down, then it is very hard to be profitable.

(4) The CEO owns not many shares and not sure whether he cares about making a profit. However, two of its co-founders still are with the company.

5. Conclusion
It seems to be a disruptive product and the growth is good. However, it still loses money and it is far from sure whether it will continue to grow and whether it will be profitable in the future.

6.Links


theScore, Inc. (SCR.V)

Website
Yahoo Finance
Filing

July 24, 2018
Q3 2018 Data, Year end: Aug. 31th
Price: $0.36, Shares: 296m, Cap: $107m
1.Basic Information
(1) History 
John Levy,  son of Cecil who owned a cable company at Hamilton in 1990,  found the sports media company which operates the Score sports TV channel. Later it was sold to Rogers for $167m at 2012. In the deal, it excluded theScore mobile App which later became the major product of theScore Inc. John Levy continues to build the new company and it was IPOed at that same year. It was able to grow the revenue to over $25m by 2017.

(2) Business-related.
Products:
1. TheScore App: This is the major sports app it offers. It generates most of the Ad revenue. Currently, it has around 4m active monthly users. The company creates its own media content for the app. Also, it allows the users to set their own preference so the content is more relevant to the user.

2. eSports: Computer gaming sports.

3. Online Sports Betting: Not quite sure whether it is legal to do so in the U.S.A. But the company seems very interested to get into this business.

It seems the first quarter(Nov. 30th) is its strongest quarter. While last quarter(Aug. 31th) is its lowest quarter. The other two quarters are close to the average number of this two quarters.

(3) Management.
John Levy: John successfully found the TV company and sold it to Rogers. He is very open-minded and always looking for changes. Previously when he sold the TV channel to Rogers. He intentionally excludes the mobile app from the deal. It is very impressive that how fast the company grows Ad revenue from this app.

Benjamin Levy: President and COO and John Levy's son. He seems to be the COO of the previous TV company.

(4) Debt and Credit Facility.
Currently, there is $11m debt outstanding. The interest rate is around 5% to 6%. Cash is around $5m.

(5) Insider holding, options, Insider trading info, share buyback.
John Levy: 62m shares, 20%.
Benjie Levy: 5m share. around 2%.
JOHN ALBRIGHT: Director, 51m shares,  Relay Venture. 

(6) Employee numbers


(7) Industry comparison.
ESPN: is its major competitor.
Yahoo Sports:


(8) Major events



2. Financial data.


3. Valuation
(1) Currently, the company generates no profit. May just close to cash even. It is hard to evaluate it based on profitability.

(2) If just based on revenue, it generates around 30m revenue currently. The current market cap is close to 4 times its annual revenue. Not really cheap.

4. Risk
(1) Generally, Ad revenue is very bad revenue source since its customer can easily cut back on marketing spending and also it can easily lose customers.

(2) It is hard to tell whether it can continue growing its user base. The competition in mobile apps in very tough. It is losing users on the Android platform.

5. Conclusion
The company was managed very well and grew very well. However,  it is still a very risky business and the current price is not cheap.

6.Links


H2O Innovation Inc. (HEO.V)

Website
Yahoo Finance
Filing

July 16, 2018
Q3 2018 Data
Price: $1.28, Shares: 40m. Cap: $51m
1.Basic Information
(1) History 
This is a Quebec company started in the 1990's. Originally it was called Hebron Fjord Resources which is a junior mining company. Guy Goulet(CEO at that time) and FrĆ©dĆ©ric DugrĆ©(Current CEO) seems to be among the original owner. At 2000, it changed its name to H2O Innovations and started to invest in water treatment technologies. It IPO'ed 2001 at $0.50. The symbol is HOI and later changed to HEO at around 2015. It had a revenue of around $4m level at that time and with quite big losses every year. The revenue was down until 2007 it returns $7m level but still losing money. At 2008, FrĆ©dĆ©ric DugrĆ© took over as CEO. Revenue increased to $10m but still in loss. In 2009, revenue tripled to $31m and cash positive. However, in 2010, revenue was down again and didn't recover until 2014. There was a big write off of $10m+ in goodwill and intangibles during this period.  The company achieved EBITDA positive since 2013. Revenue grew to $50m at 2015 and 2016 and to $80m at 2017. Revenue of 2018 expected to be close to $100m.

Originally the company was only doing the water treatment business. Lately, from 2009 to 2013, it added the maple syrup equipment business. At 2016, it added operation and maintenance business for wastewater facilities.  Now all three business accounts 1/3 of revenue for each.

(2) Business-related.
Water treatment: This is its old business. Most are project based which makes revenue fluctuating. Now it only accounts for 1/3 of its revenue. It seems a tough business and the company barely made any money from this business.

Maple syrup equipment: This business is more predictable and seems growing very well.

Operation and maintenance for water facilities: This is mainly a service. It is more ideal for its revenue is very consistent and it is capital light. However, currently, I don't know what is the margin like.

(3) Management.
FrƩdƩric DugrƩ: He is the original SVP of the company since the beginning. Took over CEO role since 2008. During his time, the company did better in terms of reduced losses. Also, the company grew revenue from $30m level to $100m level currently. However, during his time, the company still incur losses. Also, issue shares quite loosely.

(4) Debt and Credit Facility.
Currently, there is $11m debt outstanding. The interest rate is around 5% to 6%. Cash is around $5m.

(5) Insider holding, options, Insider trading info, share buyback.
FrĆ©dĆ©ric DugrĆ©:  850k Shares, only 2%. Overall his compensation is quite moderate. At 2017, the company issued close to 1.5m shares of options at $1.65 to him.

(6) Employee numbers


(7) Industry comparison.


(8) Major events



2. Financial data.


3. Valuation
(1) Current the company is just cash positive. It is not really cheap from profit aspect. However, It might be able to generate $5m/year cash in the future if it can improve profitability. Also, it might be able to continue growing its revenue.

(2) The CEO, CFO, COO holds 2.5m shares of options at a price of over $1.65 which is a good incentive for them to do well.

(3) Currently, the company is making a small profit or close to making a profit. The book value is also close to share price. It decreases the risk.

4. Risk
(1) The company never made any big profit and it might not make money even though the revenue is much higher.

(2) The management tends to issue shares very loosely and it might keep doing that.

(3) There are quite a lot wrote down of goodwill and intangibles during the past. Those acquisitions the company made seems not very good.

5. Conclusion
The company wasn't managed very well. However, the current price is acceptable as long as it can maintain cash positive.

6.Links


Akumin Inc (AKU-U.TO)

Website
Yahoo Finance
Filing

May. 16, 2018
Q1 2018 Data
Price: US$4.08, Shares: 60m. Cap: $250m
1.Basic Information
(1) History 
The company was founded around 2014 through the restructuring of 13 independent out-patient imaging center in Florida called Elite imaging. Gradually it acquired and consolidated more imaging center in the US. Today it has 74 imaging center across several states in the US.

(2) Business-related.
MRI: Current MRI counts 50% of the total revenue. There is a big price difference between the hospital and the independent lab like Akumin. Usually, the hospital might charge over 2x over the lab. Also, it seems the reimbursement from the government dropped a lot as well. It was quoted by the CEO Zine that 10 years ago the reimbursement of one MRI procedure was around $1000, but now only $230. Currently, the margin is only about 15% compare to 50%+ 10 years ago. Once consolidated, the company declared to be able to increase margin by 10%.

Around 70% of its revenue is paid by the insurance company. Around 20%  is paid by Medicare & Medicaid.

(3) Management.
Riadh Zine seems to be the key person in this company. Previously he was a Managing Director in Global Investment Banking at RBC. He did quite some big M&As and IPOs.  Later in 2013, he co-founded Roadmap Capitals Inc. It seems a VC firm and invested over $100m in high tech sectors.

(4) Debt and Credit Facility.
Currently, there is US$72m debt outstanding. Currently, it has US10m in cash.

(5) Insider holding, options, Insider trading info, share buyback.
Riadh Zine: 3.5m shares, 800k options, 900k RSUs. Total close to 10%.
By Q1 2018, there are 51m shares outstanding. 1.2m warrants, 2m RSUs.

(6) Employee numbers


(7) Industry comparison.
Radnet: 306 imaging center. $900m+ revenue. $100m EBITDA, $15m net income.  Cap over $600m.

SimonMed Imaging: 72 center. Private company.

LabCrop: $10B revenue. Net income $800m. Cap $17B

Quest Diagnostic:  $8B revenue. $800m net income. $14B cap,


(8) Major events
At May 2018, the company issued 8.75m new shares at US$4.00/share for $35m. There might be more to issue at the price.

At May 2018, the company purchased all the minority interest for $21.6m + $3.7m in shares. It is a reasonable move since it paid $0.95m at Q2 2018 in minority interest.


2. Financial data.


3. Valuation
(1) At Q1 2018, the company made $33m in revenue. $6.8m in adjusted EBITDA. $1.1m in net income after $0.95m minority interest payment. If we add that back, net income is $2.1m.

(2) The medical labs are going through consolidation lately. There is plenty of opportunity for the company to grow. If it does well, the upside is pretty high.

(3) Assuming by 2020, it can $200m in revenue, $40m in EBITDA, $30m income, $600m Cap. 70m share. It supports a price of $8.5. 

4. Risk
(1) The government might decrease the reimbursement which will affect its profit greatly as in the Vimed cases.

(2) Its growth plan might not work well which won't turn into growing profit. Also, growth might stop.

(3) It seems like issuing shares too loosely.

5. Conclusion
Although the company is a new IPO. It is very profitable and growing well with strong management. The price is not cheap if based on current earning. But if the company continue its current trend, it is actually worth much more than the current price.

6.Links

BNN interview


Mar. 29, 2019
Price: CA$4.79. Shares 62.4m. Cap: CA$300m.
2018 Data (in US$)
(1) For full-year 2018, revenue is $155m, EBITDA $32m. Real cash generated is around $15m. Debt $113m. EV/EBITDA is around 10 times.

(2) Assuming by 2021, revenue $250m, EBITDA $60m. Debt $150m. 75m shares. Real income $30m, Cap $600m, Support CAD$10.6 share price.

Pioneering Technology Corp. (PTE.V)

Website
Yahoo Finance
Filing

Apr. 17, 2018
Year-end Sept. 30. Dec 2017 Data
Price: $0.445, Share outstanding 56m. Options 3.5m below $0.3/share. Cap: $25m
1.Basic Information
(1) History 
The company was founded by Dr. Reza Shah, a former NASA engineer, in 1998. He is an inventor of many items. In 2002 Kevin Callahan joined the company and started to commercialize those inventions. The company IPOed at 2005 through a reverse merger. In the beginning, the company has several products besides the Safe-T-Element. It is mainly a fire prevention technology for the electric stove. Reza Shah died around 2008. Callahan continues to commercialize those products. It did quite well and reached $3m in revenue and almost profitable at 2010. Then for the next 3 years, it had some drawbacks. Since 2014, it started to pick up again and reached record revenue of $10m in 2017. Lately, at  Q1 2018 the revenue was down surprisingly caused by its major hotel customer postponed delivery to Q2 and Q3 of a big project. The stock price fell from above $1 to currently 40c level.

(2) Business-related:
1) SmartBurner: This is the standalone coil burner replacement. The retail price is around $200 per set of 4 burners. Recently it has been picked up in sales volume. It can be used by the general household. However, I think the adoption rate of this product by general household is very low.

2) Saft-T-Element: This is the non-standalone coil burner which needs professional installation on the stove. I guess its cost should be cheaper than the standalone burner and it is more effective than the standalone ones. This is mainly used in hotels and multi-unit apartments.

3) Saft T Sensor: This is a sensor for the microwave. When it senses smoke, it can shut down the microwave power supply. It works best for students dormitory which false alarm from microwave causes a lot of headaches.

4) Range-Reminder: Replacement dial ring on the stove to remind user if cooked for a certain time. It is quite complicated to setup and I don't think this will be popular. However, it can be useful for the OEM manufacturers because they can implement it in their products.

The smart burner is their major product and it best to be used for hotels, rental apartment, student dormitories and people who often forgetting they are cooking. However, there is a concern that the smart burner will take a longer time to cook and might not hot enough for cooking something. It should do a better job of marketing their product.

Also, it seems that its technology should be very attractive to OEM stove manufacturer. However, they seem not very interested in this company. There is a UL858 regulation which requires the stove to contains certain fire prevention. It will be a requirement after April 2019. Don't know how those manufacturers will act to this regulation.

(3) Management.
Callahan is the key person in this company. He did a good job running the business, although there are some losses in the previous years. They are not that big. He raised money at the right price point. Also, he seems pretty good in loading those commercial clients.

(4) Debt and Credit Facility.
At Dec. 2017, it has $8m in cash and no debt.

(5) Insider holding, options, Insider trading info, share buyback.
Callahan holds 2.57m shares, close to 5%.  1.35m options with an exercise price below 0.22/share.

(6) Employee numbers


(7) Industry comparison.
It seems there is no direct competitor to its product. However, major stove OEM manufacturer might be able to come up with something similar or with different technology.

(8) Major events


2. Financial data.
3. Valuation
(1) Based on 2017 and 2016 number, it has generated around $1.3m in real income. Currently, the price is around 20 P/E. Not really cheap. However, since there is $8m cash on hand, if the company can maintain its profitability, the price can be supported.

4. Risk
(1) Its revenue is concentrated on major customers and rely on big projects. Future revenue may fluctuate greatly.

(2) Its retail and marketing to the general public is weak and may never be popular products.

(3) It seems unable to attract the OEM manufactures.

5. Conclusion
Based on current revenue, the company is traded not cheaply. If the company can restore growth, the price is very acceptable.

6.Links
Interview

Interview

Distinct Infrastructure Group Inc. (DUG.V)

Website
Yahoo Finance
Filing

Apr. 10, 2018
Q3 2017 Data
Price: $1.48, Share outstanding 46m. Options 3.6m at $1.48. Cap: $68m
1.Basic Information
(1) History 
Joe Lanni and Alex Agius were friends in college in the early 2000's. They both worked in the construction industry for several years.  In 2007 they co-founded the company as a small contractor for construction projects. At 2009, Alex started to work full-time for the company. The company grew rapidly from $10m revenue at 2010 to $60m in revenue at 2016. 2017 revenue is expected to be over $90m. The company grew mostly from organic. It IPOed at Sept. 2015 through a reverse merger.

(2) Business-related:
1) Telcom market: Provide fiber cable installation for Bell and others etc.

2) Hydro market: Provide maintenance service I guess.

3) Government projects:

(3) Management.
Joe Lanni and Alex Agius both seem to be entrepreneurs and very focused on growing the company. Previously they both worked in the construction industry for several years and it seems they managed the company pretty well. However, they seem to focus on growth than profitability. Also, the company's debt was growing to fast in my opinion.

(4) Debt and Credit Facility.
At Sept. 2017, it has $5m in cash and the following debt:
1) $12m term loan from RBC due May 2022. The interest rate is banker's acceptances rate + 1.85% to 2.85%.  The effective rate should be around 3.5%.

2) $29m revolving loan from RBC. Interest rate similar to the term loan. $27.8m outstanding.

Debt covenants: Debt/EBITDA < 4.25:1 at Sept. 2017, < 3.5:1 at Dec. 2017.

(5) Insider holding, options, Insider trading info, share buyback.

At end of 2016, both Joe and Alex holds around 6.8m shares of the company which is around 20% each at that time. With the recent financing at $1.35/share, don't know how much they own now.

(6) Employee numbers


(7) Industry comparison.


(8) Major events
1) At Nov. 2017, the company acquired Crown Utilities, a Manitoba based utility installer for $13m in cash plus 3m share valued at $1.35/share. Also, it raised $10.2m from issuing 7.6m shares at $1.35/share. Crown Utilities has around $20m in revenue and $4m in EBITDA.


2. Financial data.
3. Valuation
2017 EBITDA is around $9 to $10m. It might be able to increase to  $15m in 2018. EV/EBITDA is over 10. Not really cheap. However, the company is growing very consistently in the past several years.

Assuming $15m EBITDA, 50m net debt. 10 EV/EBITDA,  50m shares, it should support a $100m Cap and $2/share price.

4. Risk
(1) The major issue with the company is that its receivables and work in progress keep going up. It has to issue new debts and shares to keep up the working capital needs.

(2) Its working force has been unionized which has increased its cost and might cause trouble in the future.


5. Conclusion
The company's growth is very good and profitable. Current price is acceptable. However, the company needs to bring down its receivables and working in progress. Needs to watch closely.

6.Links
Interview

Desert Lion Energy Inc(CVE:DLI)

Website
Filing

Mar. 15, 2017
Price: $1.4 Shares: 46.3m. Cap: $65mm
Summary


1. History 
The company was created around in the middle of the year 2016. It raised around $27m so far and purchased the interest of two abandoned lithium minings in Namibia. Previously those minings were producing lithiums and other materials. Because of the lithium price raise lately, the leftover lithium deposit in those mining became interesting again.

At end of 2017, it started to produce 2% lithium concentrate from its stockpile of around 700kt. It estimated to be able to create 150kt to 160kt of 2% lithium concentrate in the next 12 to 18 months. All the final product will be sold to Jinhui Lithium, a Chinese Lithium carbonate producer. At 2018, it is expected to generate around US$15m to US$20m in EBITDA from the lithium concentrate sale.

The company has a 3 phases plan which is 1) Produce concentrate from stockpile 2) Mining and produce of 250kt to 300kt concentrate per year. 3) Produce 25kt lithium carbonate per year. Phase 1 is already started. They are working on phase 2.


2. Business
(1) The main resources DLI holds is Lepidolite(contains Li2O), the second most common type of resource for Lithium. Around 10% of Lithium were produced from Lepidolite. The original ore mined which contains around 1% or less Li2O first is converted to lithium concentrate which contains 1.7% to 6% of Li2O. Most likely is 2% or 4%. Then the lithium concentrates will be processed and converted to 99.5% lithium carbonate(Li2CO3) which can be used to create lithium battery. Also 99% lithium carbonate is usually used in the industrial application like glasses and ceramic.

(2) Lithium price:
At 2017, 6% Galaxy resources sold 120kt spodumene lithium concentrate roughly was traded for US$900/mt. Generally, spodumene is higher in price than lepidolite. At Sept 2017, 4% lepidolite lithium concentrate was quoted for US$315/mt in price by Chinese media. On its Nov. 2017 technique report(P142), the 2% concentrates is estimated at US$195-$220/t including shipping fee.  I estimate the price might be around US$150/t to US$180/t net for DLI.

The 99.5% Lithium carbonate in China currently is priced US$24,500/mt, down from the top price of US$26,000/mt. International, its price around US$16,000/mt. Don't know why there is the big gap.

(3)Margins:
Lithium concentrate: I estimate it might generate US$22m to US$27m in revenue from the stockpile concentrates sale to Jinhui. Based on EBITDA of US$15m to US$20m, the margin might be 60% to 70%.
As for phase 2, since there is extra mining cost, the margin should be much lower.
For phase 3, currently, the margin to produce Lithium carbonate is quite high. It could generate as much as 70% gross margin. If combined the with the concentrate margin. It could be even higher.

(4) CapX:
The phase 1 CapX seems quite low. Also, it shouldn't be very costly to construct phase 2. However, phase 3 might be very expensive to construct.

3. Industry, Competitors
(1)  American Lithium Corp. (TSXV:LI)

(2) Advantage Lithium Corp. (TSXV:AAL)

(3) Wealth Minerals Ltd. (TSXV:WML)

(4) Galaxy Resources (ASX:GXY)

The company is an Australia spodumene mining. At 2017, it shipped 120kt of concentrate for around US$900/mt.

4. Management



5. Share information
As of Mar. 2018, there are 46.3m shares outstanding. Options 4.6m and warrants 8.7m.

6. Major events
At Mar. 2018, it entered an offtake agreement with Jinhui Lithium to sell all of its lithium concentrates to them. Also, Jinhui has the options to subscribe 15% of DLI shares for CAD$13m. Which valued the company at $1.59/share.


7. Financial data.

8. Balance sheet and debt information.
At Mar. 2018, the cash balance is around $10m. No debt.

9. Valuation
(1) The 150kt concentrate might generate US$25m revenue.  Theoretically, phase 2 could generate around US$40m/year sales. Phase 3 could generate US$600m/year sales.

(2) Currently, it might be able to generate US$15m to US$20m EBITDA in 2018. Currently, the Cap is just 4 times of the EBITDA. Seems quite cheap. However, the stockpile is just for one year sale. It needs to proceed to phase 2 to be able to generate future EBITDA.

10. Risk
(1) The biggest risk is lithium price. There might be an oversupply in the future.

(2) Just phase 2 will not be enough for the company. It is very costly to construct phase 3. Also, it might have environmental issues.

Conclusion
It is quite a cheap price for a production mine. However, it is still in the early stage. Still quite risky.

Refs
Lithium price:
https://tradingeconomics.com/commodity/lithium



Temple Hotels Inc(TSE:TPH)

Website
Google Finance
Filing

Feb. 26, 2018
Q4 2017 Data
Price: $2.57, Share outstanding 25.3m. Cap: $64m
1.Basic Information
(1) History 
The company was IPOed in early 2007 at a REIT trust. At that time, it only has a 180-room hotel in Moose Jaw, Saskatchewan called Temple Gardens Hotel and Spa. It was externally managed by Shelter Properties Ltd., a company controlled by Arni Thorsteinson who is also the CEO of Temple REIT.

Since 2007, the company pursued pretty aggressive growth by acquiring more hotels, especially at 2007 and 2013, by end of 2014, it had 32 hotels with around 4100 rooms. The growth was mainly done by mortgage and debts which made it became very high leveraged. It became a problem when west Canada's economy trended down because of the drop in oil price.

In 2014, Morguard Corporation, a multi-billion public RE company run by Rai Sahi, started to purchase the company's shares and collected 4.7m shares which are 11.5% of total 41m shares by year-end.

In May 2015, Centennial Group Limited, a 5% shareholder, started a proxy fight with the company and it led to new board election including Rai Sahi from Morguard and two others from Centennial.

In later 2015, the company did a private offering of $40m for $1.1/share. At end of 2015, Morguard, through the private offering, owned 30m shares which are 39% of total 78m outstanding shares.

On April 01, 2016, the company transferred its management from Shelter to Morguard. At the same time, Rai Sahi replaced Arni Thorsteinson as new CEO of the company.

In Dec. 2016, the company did another $50m private offering for $0.67/share. Increased total shares to 151m. Morguard increased its shares to 85m which is 56% of total shares.

In June 2017, the company did 6 for 1 share consolidation. As a result, it now has 25.3m shares. Among which Morguard has 14.1m which is around 56% of total shares.

(2) Business-related:


(3) Management.
Rai Sahi is the key person in this company right now. He is an immigrate from India in 1971. After working for several years, he created his own trucking business and later entered real estate at around 1996. His company is now called Morguard Corporation which owns and manages over $17b real estate.

(4) Debt and Credit Facility.
By Q4 2017, it has following debts:
(1) $370m in mortgage debt. The average interest rate is around 5%. It was not in compliance with coverage ratios with 6 mortgages total around $100m.
(2) $13.5m Revolving loan provided by Morguard. Prime rate +2%.

(3) $41m convertible loan due on Sept. 30, 2020. Interest rate 7.25%. There is $2.2m redemption each year. Converting price $9.75

(4) $34m convertible loan due Mar. 2018. It will be repaid since Morguard issue a new $35m facility for $6.5% on Feb. 2018.

Totally the company has around $450m in debt. It has to pay around $25m in interest. Also, the company's total asset is around $460m which is almost the same as the total debt. Mainly because there was quite a lot impairment in the past few years.

(5) Insider holding, options, Insider trading info, share buyback.
Rai Sahi: Holds 14.1m(56%) shares through Morguard Corporation.

(6) Employee numbers
Not important

(7) Industry comparison.


(8) Major events



2. Financial data.
3. Valuation
(1) With distressed oil price, the company still be able to generate around $14m in Fund From Operation(FFO). While current Cap is 64m. The yield of FFO to market cap is around 21.5%. By average, REIT should be traded less than 10% of FFO. That gives room to double the current price if it is priced fairly.

(2) Currently, all the hotels in Alberta simply are not making money. If the company sell those hotels, the company will be able to deduct 2/5 of its debt and the profit will still be the same. However, that doesn't reduce leverage ratio that much since currently the company's equity is really low.

(3) Before 2015, the appraised value is always higher than the cost of acquiring those hotels. Now the book value of all those hotels is around $430m while the original cost is over $730 by my estimation. I think the fair value of those hotels should be no less than $550m. That gives a $120m in addition to book value which is around $4.8/share.

4. Risk
(1)Unlike OTEL, who's earning is stable but the debt interest rate is too high. This company needs to improve its profitability before it can make it to lower leverage. Although current RevPar is low and is improving, there is the risk that it might go down again.

(2) Competition from lodge sharing service like Airbnb might be a threat to the whole lodging industry.

(3) Now with both convertible debt been extended to the year 2020, although its debt level is high and it is not in compliance in some mortgage debt terms, its debt actually is not a big issue for now. It can pay down some individual mortgages if the talk fails. Also, it has the choice to sell some of the nono performing hotels. Most of the hotels are booked below the purchase price now.

5. Conclusion
The current price is significantly undervalued the company's real asset value. It expects the company to raise more capital and dilute existing shares. While I feel it is more likely won't need to issue any new shares and the business might also be getting better.

6.Links

Interview with Rai Sahi

Apr. 08, 2019
Price: $1.74. Shares: 50m. Cap: $87m.
(1) For 2018, it only generates $11.2 in FFO which is lower than last year's $14m.

(2) I was wrong that the company did have to raise money to cover debt repayment. It did a 1:1 share offering at $1.75/share which doubled the share count to 50m. Most of the shares were taken by Morguard. As a result, all convertible shares were redeemed. It owns Morguard by $65m. I estimated it will save $3m in annual interest which will be added to FFO.

(3) Assume by 2021, it can generate $18m in FFO. at 8% rate, it supports a $225m cap which is $4.5 share price. 

HLS Therapeutics(CVE:HLS)

Website
Yahoo Finance
Filing

Feb. 09, 2017
Q3 2017 Data
Price: US$9.25, Shares: 27m. Cap: $313m?
1.Basic Information
(1) History 
It was created by the former management of Biovail in 2015.  HLS raised US$385m(USD$200m from stock offering of US$10/share and US$185m debt) and acquired the North American rights to Clozaril, a medicine for resistant schizophrenia for US$305m from Novartis.  At Dec. 2017, it entered an agreement with Automodular (CVE:AM.H), a shell company to do a reverse merger at US$9.25/share valuation. The vote is scheduled at Mar. 6 and expect to close shortly after it.

(2) Business-related:
Colozaril: Acquired in August 2015 for $305m. It generated $46m and $36m revenue for 2016 and 3Q of 2017.

It also acquired rights to market Absorica in the US from Galephar Pharmaceutical for $17m payment plus future royalty,  Absorica is an oral pill to treat nodular acne. In the first 3Q, the company received US19m in revenue which seems well-exceeded expectation. Partially it was because one of its competitors called back a product since early 2017.

The company also acquired distribution right of Vascepa in Canada at Sept. 2017 with $5m up-front payment and following payments. Vascepa is an omega 3 prescription drug by Amarin Corporation plc (NASDAQ:AMRN). It generated revenue in US about $46 in Sept. 2017 quarter.

(3) Management.
Biovail Filing
Most of the management previously were worked for Biovail.  Biovail is a public Canadian drug company which had committed accounting fraud at around 2001 to 2003 time. At 2010, it merged with Valeant. In 2015, Valeant was also criticized for price hiking of its drugs and the stock dropped by 90% since then. However, based on the below information. The management team of HLS was not part of the troubled period for both companies.

Chairman Bill Wells:  He joined Biovail in 2005 as an independent director. At that time he was the CFO of Loblaws. After former CEO Eugene Melnyk left Biovail in 2017, he became the CEO of Biovail from 2008 and 2010. He led the turnaround and the merger with Valeant. I think he did a good job on that. He left the company right after the merge.

CEO Gregory Gubitz: SVP of Biovail from 2006 to 2010.

COO Gilbert Godin: SVP, COO of Biovail from 2006 to 2011.

Chief Scientific Advisor Chris Fibiger: CSA of Biovail from 2008 to 2010.

VP  Integration Management Carmel Daughtery: VP Integration Management of Biovail from 2005 to 2010

VP Intellectual Property Rochelle K. Seide: VP Intellectual Property of Biovail from 2009 to 2011


(4) Debt and Credit Facility.
Currently, there is US$150m?? debt outstanding. Currently, it has US35.7m in cash. After the merger, it should have around US$55m in cash.

(5) Insider holding, options, Insider trading info, share buyback.
Bill Wills: 1.2m shares + 250k options +260k PSU.  5.4%
Joe Maclean(Director): 1.9m shares +250k options +260k PSU.  7.5%.
Gregory Gubitz:  667k shares + 250k options + 260k PSU. 3.7%
Gilbert Godin: 900k shares + 250k options + 260 PSU. 4.4%.

(6) Employee numbers


(7) Industry comparison.


(8) Major events



2. Financial data.


3. Valuation
(1)Currently,  it has US$180m in equity and US$30m in losses. It has 25,277,997 in total shares. For 2016 and 3Q 2017, it generated US38m and US$40m in EBITDA. By estimate, it might generate US$55m in EBIDTA at 2017. It has cash of US$35.7m and has a debt balance of around US$156m.

(1) . If using US$55m as annual EBITDA,  US$9.25 as current price, its EV=9.25*25.3+156-35.7=$354m. EV/EBITDA = 354/55=6.5. Not that high actually. If adding AM's new equity and cash, the EV will still be the same since the Cash and added equity will be even out.


4. Risk
(1) The public reception of any person related to Biovail and Valeant is pretty bad. The company might be precepted as a replica of Biovail or Valeant which is not good for a public company. However, since the management is not involved in the bad deed of both companies. Eventually, the financial number will speak for itself.

(2) The good Absorica performance is partly due to competitor's callback. Once it is back, Absorica revenue might down significantly.

(3) All the drugs might subject to competition from new drug from generics.

5. Conclusion
Although this is a new stock, it generates steady cash and EV/EBITDA. If it can keep business stable, the price is acceptable. If it can acquire more drugs, then this could a very good one.

6.Links

Mar. 16, 2018
Current Price $11.5, shares 27.3m. Cap: $314m
1. The new HLS share started trading at Mar. 14. Current price equals roughly US$8.84 which is lower than the $9.25/share price and all previous private placement.

2. Assuming US$60m EBITDA at 2020, 10 EV/EBITDA, US$100m net debt, 1.3 USD/CAD rate. 28m shares. Its price can be (60*10-100)*1.3/28=CAD$23.2.


Aberdeen International Inc.(TSE:AAB)

Website
Google Finance
Filing

Jan. 30, 2017
Oct. 2017 Data (Q3 2018) 
Price: $0.19, Shares: 95m. Cap: $18m
1.Basic Information
(1) History 
Stan Bharti was the key person in this company. He is a mining expert and in 2002 he created a private investment bank called Forbes & Manhattan. The company invested in potential small resource deposit and actively manage and help the mining to exploration and running the business. Then after several years, it brings the resource company to the public. It was a very successful model and in some cases, returned hundreds of times.

Aberdeen was very small resource investment fund created around 1997. It was less than $1m in assets until Stan Bharti along with George Faught came in at 2005. They changed the company to provide funding for Forbes & Manhattan's private mining companies. Between 2005 and 2007 the company raised $10m and $60m accordingly. It did quite well before 2011 with $70m in retained earning. However, for the next 5 years, it lost around $90m, basically all the retained earnings because of the downturn in the mining sector.

At end of 2014, activist investor Ryan Morris along with a fund holding 9% of total shares started a proxy fight with Stan Bharti. Seeking to replace all directors but failed in the share holder's vote. In response, the company replaced 3 directors. Since then At 2016 and first 3Q of 2017, the company earned back around $20m.

(2) Business-related:
Major holdings:
A) Lithium X(CVE:LIX)(PLASA): 30% of book value. 
Lithium X Filing
At end of 2015, Aberdeen acquired a Lithium minging called Diablillos project(also called PLASA) at Argentina for $5m.

In April 2016, Aberdeen sold 50% interest of PLASA to Lithium X(CVE:LIX) for 8m shares of Lithium X. Lithium X's share price raised to around $2. Making Aberdeen's holding value of it worth $15m. Aberdeen reduced Lithium X's shares to 4.2m by Jan. 30, 2017. Reduced again to 1.4m by Apr. 30. 2017.

In June 2017, Aberdeen sold remaining 50% interest of PLASA to Lithium X for $5m plus 6m shares of Lithium X. Among which 3m shares is on hold until Nov. 11, 2017, 3m shares are on hold until May 10, 2018. Also, Lithium X will issue to Aberdeen an additional 3,000,000 LIX Shares if, during the three years following closing, the volume weighted average trading price of LIX Shares is $3.00 or more for a period of 20 consecutive trading days. The total cost recorded in Lithium X for the PLASA project is $33.8m.

By Q2, 2008(July 31, 2017), Aberdeen seems sold all previous 8m shares. Just holding 6m shares from the second sale.

On August 10, 2017, Aberdeen purchased 1%  smelter returns royalty of PLASA project as previously agreed for $1m plus 7m AAB shares which valued around $930k.

By Q3, 2018(Oct. 31, 2017),  Aberdeen still holding those 6m shares. It is unknown whether it still holds those after that because it can sell 3m shares after Nov. 11, 2017. Based on the 6m shares, the value of LIX holding itself could worth $15m already which is close to the whole AAB market cap.

At Dec. 18, 2017, Lithium X announced to be sold for $2.61/share to a Chinese company called NextView. The vote will be held at Feb. 2018. There is breakup fee of $16m by Lithium X and $20m by NextView accordingly if one party break the deal.

Overall, Aberdeen has made close to $30m on this investment. It was really a good return. I feel it might vote no on this deal since it needs to give up the 3m stock if LIX share price rises above $3. However, if Lithium X give the company some compensation for that. It might agree to the deal. Even ABB vote no on the deal. The deal might still be done without AAB's vote. The deal is quite possible given the breakup fee is quite high for both sides and the Chinese company actually made a deposit for that purpose.

(Feb. 06) The deal actually passed in shareholder voting.

B)Fura Gems Inc(CVE:FURA): 20% of book value
Filing
Gemstone mining in Colombia and Mozambique, currently AAB holds 13m shares might account around 18% of total FURA shares. It has 3 mining licenses including one production and one exploration license in Colombia, and one exploration license in Mozambique. The production mine in Colombia is in very low volume and in manual mode. The company is planning to improve it.

C)Desert Lion Energy Inc: 12% of book value
Website
Filing
Private Lithium mining in Namibia. It started production at Oct. 2017. Will go public through a reverse merger with Camex Energy. The vote is set at Feb. 15. Each 12.0258 share of Camex will be converted to 1 new share. The latest private placement of Desert Lion is $1.82/share.


D) African Thunder Platinum Limited: 10% of book value
It is private platinum mining. The company spent around USD$15m. Currently been suspended due to low platinum price. It was sold to a company which will be public.  It might be able to get the $5m on the book back.

(3) Management.
Stan Bharti


(4) Debt and Credit Facility.


(5) Insider holding, options, Insider trading info, share buyback.
Stan Bharti: Previous to 2009, he only owns 500k shares. Increased to 8m shares by end of 2009. Reduced his shares to 5.5m by end of 2011. Reduced his shares to 800k by end of 2012.  Increased again to 3.6m by end of 2013.  Increased to 5m by end of 2014. Increased to 7.3m by end of 2015. Increased to 19m by end of 2017. Which is around 20%.

George Faught: Founder and original CEO from 2006 to 2012?. As Jan. 2017, he holds 6.5m shares(7.3%).

David Stein: COO and CEO from 2009 to 2016. Succeeded by Stan Bharti. As Jan. 2016, he holds 7.1m shares(8%). Since he resigned in 2016, at Jan. 2017, his share was not disclosed in MIC.


(6) Employee numbers


(7) Industry comparison.
PINETREE CAPITAL
Previously I have invested in Pinetree's secured debt. Pinetree was very similar to AAB which is a fund invested in junior resources. However, it took too much debt and it only invested in public companies. Both suffered greatly during the resource downturn. Pinetree was eventually been liquidated as 3c/share.



(8) Major events



2. Financial data.
3. Valuation
(1) Currently, the company is traded around 1/3 of its book value. Looks very cheap. However, in the past, it was always been traded less than half of its book value. Sometimes around 1/3 of the book value as well.

(4) Since 2016, AAB has shifted strategy to take a major position on private mining properties. It is more close to the way  Forbes & Manhattan works. It actually worked on PLASA investment which returned close to $30m for an initial investment of $5m.

(3) Currently, the value of LIX holding itself actually worths close to the market cap of the whole company. If the LIX deal goes through, the company will have over $15m in cash. It could make good use of it. (Feb. 06: The deal passed)

(4) The Fura Gems shares appreciated quite a bit lately. However, the mining has some medium risk. Not sure whether it will work.

(5) The Desert Lion is another Lithium mining which will very likely be successful. Need to watch out once it goes public.

(6) The African Thunder mining is a failed investment the total $15m would be zero if the platinum price stays low.

4. Risk
(1)The company seems not shareholder friendly. It paid a lot to management in the previous years. Also, after the proxy fight in 2015, the company even stopped to update its website. However, since now Bharti owns 20% of the company, at least his interest is aligned with shareholders.

(2)The resource segment is still very weak. It might take a long time to recover. Like the platinum price, if stay low for a long time, the African Thunder might be worth nothing.


5. Conclusion
Although the company did pretty badly in the past several years. With it shifts its strategy on several major projects likes Forbes & Manhattan did, it might do very well if the mining sector continues its recovery. Given the big discount to the book value, this seems to be a very attractive stock.


6.Links